<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210214050353N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-16</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effectiveness of cognitive behavioral therapy using virtual reality-based exposure and response prevention ( VR - ERP ) and cognitive behavioral therapy in OCD</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of cognitive behavioral therapy using virtual reality-based exposure and response prevention ( VR - ERP ) and cognitive behavioral therapy in adults with obsessive-compulsive disorder-contamination/washing</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-10-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54374</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the Restricted Randomization method of block randomization will be used. Blocking is usually used to balance the number of samples assigned to each of the study groups. This feature helps researchers to equate the number of samples assigned to each of the study groups in cases where intermediate analyzes are required during the sampling process, so that the number of samples assigned to each of the study groups become equal and in this study, we will have 4 blocks. Excel software was used to generate a random sequence. Allocation concealment is also used, which is the method used to execute a random sequence on study participants. In such a way that the assigned group is not known before the individual is assigned. Using Sequentially numbered, sealed, opaque envelopes, each random sequence created is recorded on a card. And the cards are placed in the envelopes of the letter, respectively. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Finally, the lids of the letter envelopes are glued and placed inside a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants into the study, one of the envelopes of the letter is opened in order and the assigned group of the participant is revealed, Blinding description: Evaluator and statistical analysts are blind to the research process. . Statistical analyst is blind to research so that data analysis can be done without bias.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Obsessive-compulsive disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: cognitive behavioral therapy using virtual reality-based exposure and response prevention (VR-ERP) therapy : At first, Participants will complete the questionnaires as a pre-test including: Yale-brown obsessive compulsive scale, Beck Depression Inventory, Beck Anxiety Inventory, Obsessive beliefs questionnaire-44, World Health Organization Disability Assessment Scale-2. Then, they enter the training phase to get used to moving in the virtual environment. In this stage, they encounter a natural environment in the living room and do a number of tasks such as check the room for a few minutes, turn on the TV, Move objects inside the shelves. Then, Then, they enter the experimental phase. This step includes 12 sessions. Individual treatment sessions are held weekly. Each session includes a discussion about the previous week's homework and an obsessive-compulsive self-assessment, cognitive reconstruction of maladaptive thoughts in 20 minutes and virtual reality exposure and response prevention in 25 to 45 minutes. Then next week's assignment, which includes reviewing educational materials, self-examination will be specified. The first two sessions focus on case conceptualization and the introduction of a treatment plan. Session 12 will be devoted to relapse prevention. Participants will then complete the questionnaires as a post-test. In follow-up phase, participants will complete the research questionnaires after 3 months. Intervention 2: Control group: Cognitive behavioral therapy: At first, Participants will complete the questionnaires as a pre-test including: Yale-brown obsessive compulsive scale, Beck Depression Inventory, Beck Anxiety Inventory, Obsessive beliefs questionnaire-44, World Health Organization Disability Assessment Scale-2. Then, they receive 12 sessions of cognitive-behavioral therapy. Individual treatment sessions are held weekly. Each session includes a discussion about the previous week's homework and an obsessive-compulsive self-assessment, cognitive reconstruction of maladaptive thoughts in 20 minutes and in-vivo or imaginal exposure and response prevention in 25 to 45 minutes. Then next week's assignment, which includes reviewing educational materials, self-examination will be specified. The first two sessions focus on case conceptualization and the introduction of a treatment plan. Session 12 will be devoted to relapse prevention. Participants will then complete the questionnaires as a post-test. In follow-up phase, participants will complete the research questionnaires after 3 months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Razieh Javaheri Renani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Mansouri Street, Niyayesh Street, Satarkhan Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613111</zip>
        <telephone>+98 21 6655 1655</telephone>
        <email>razieh.javaheri@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Razieh Javaheri Renani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Mansouri Street, Niyayesh Street, Satarkhan Avenue</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613111</zip>
        <telephone>+98 21 6655 1655</telephone>
        <email>razieh.javaheri@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Adults with obsessive-compulsive disorder of the type of contamination / washing with mild, moderate and severe severity based on DSM-5
At least Diploma education
Age between 18 to 50 years’ old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with psychiatric disorders including psychotic disorders, substance use disorder and bipolar disorder
Patients with neurological, neurological disease and no history of seizures
Patients with severe personality disorders including paranoid, schizoid, schizotypal, borderline, antisocial, narcissistic personality disorder
Diagnostic criteria of obsessive-compulsive disorder of non-contamination / washing type including ordering, symmetry, checking</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F42</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Obsessive-compulsive disorder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: cognitive behavioral therapy using virtual reality-based exposure and response prevention (VR-ERP) therapy : At first, Participants will complete the questionnaires as a pre-test including: Yale-brown obsessive compulsive scale, Beck Depression Inventory, Beck Anxiety Inventory, Obsessive beliefs questionnaire-44, World Health Organization Disability Assessment Scale-2. Then, they enter the training phase to get used to moving in the virtual environment. In this stage, they encounter a natural environment in the living room and do a number of tasks such as check the room for a few minutes, turn on the TV, Move objects inside the shelves. Then, Then, they enter the experimental phase. This step includes 12 sessions. Individual treatment sessions are held weekly. Each session includes a discussion about the previous week's homework and an obsessive-compulsive self-assessment, cognitive reconstruction of maladaptive thoughts in 20 minutes and virtual reality exposure and response prevention in 25 to 45 minutes. Then next week's assignment, which includes reviewing educational materials, self-examination will be specified. The first two sessions focus on case conceptualization and the introduction of a treatment plan. Session 12 will be devoted to relapse prevention. Participants will then complete the questionnaires as a post-test. In follow-up phase, participants will complete the research questionnaires after 3 months.</i_keyword>
      <i_keyword>Control group: Cognitive behavioral therapy: At first, Participants will complete the questionnaires as a pre-test including: Yale-brown obsessive compulsive scale, Beck Depression Inventory, Beck Anxiety Inventory, Obsessive beliefs questionnaire-44, World Health Organization Disability Assessment Scale-2. Then, they receive 12 sessions of cognitive-behavioral therapy. Individual treatment sessions are held weekly. Each session includes a discussion about the previous week's homework and an obsessive-compulsive self-assessment, cognitive reconstruction of maladaptive thoughts in 20 minutes and in-vivo or imaginal exposure and response prevention in 25 to 45 minutes. Then next week's assignment, which includes reviewing educational materials, self-examination will be specified. The first two sessions focus on case conceptualization and the introduction of a treatment plan. Session 12 will be devoted to relapse prevention. Participants will then complete the questionnaires as a post-test. In follow-up phase, participants will complete the research questionnaires after 3 months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of signs and symptoms in patients with obsessive-compulsive disorder. Timepoint: before the intervention, last session, 3 months after the intervention. Method of measurement: Yale-brown obsessive compulsive scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The symptoms of depression. Timepoint: before the intervention, last session, 3 months after intervention. Method of measurement: Beck Depression Inventory.</sec_outcome>
      <sec_outcome>The symptoms of anxiety. Timepoint: before the intervention, last session, 3 months after intervention. Method of measurement: Beck Anxiety Inventory.</sec_outcome>
      <sec_outcome>Obsessive beliefs. Timepoint: before the intervention, last session, 3 months after intervention. Method of measurement: Obsessive Beliefs Questionnaire-44.</sec_outcome>
      <sec_outcome>Disability. Timepoint: before the intervention, last session, 3 months after intervention. Method of measurement: World Health Organization Disability Assessment Scale-2.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-28</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, fifth floor Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
